Denosumab
Active ingredient: Denosumab
In short: Denosumab-bmwo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenop
What is Denosumab used for?
Denosumab-bmwo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, denosumab reduces the incidence of vertebral, nonvertebral, and hip fractures .
Denosumab-bmwo is indicated for treatment to increase bone mass in men with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy .
Denosumab-bmwo is indicated for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months. High risk of fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy .
Denosumab-bmwo is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer. In these patients denosumab also reduced the incidence of vertebral fractures . …
âš Boxed warning (FDA's strongest warning)
Patients with advanced chronic kidney disease (eGFR < 30 mL/min/1.73 m2), including dialysis-dependent patients, are at greater risk of severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported .
The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients .
Prior to initiating Denosumab-bmwo in patients with advanced chronic kidney disease, evaluate for the presence of CKD-MBD. Treatment with Denosumab-bmwo in these patients should be supervised by a healthcare provider with expertise in the diagnosis and management of CKD-MBD
Denosumab dosage
Pregnancy must be ruled out prior to administration of Denosumab-bmwo. Perform pregnancy testing in all females of reproductive potential prior to administration of Denosumab-bmwo. Based on findings in animals, denosumab products can cause fetal harm when administered to pregnant women .
In patients with advanced chronic kidney disease [i.e., estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2], including dialysis-dependent patients, evaluate for the presence of chronic kidney disease mineral and bone disorder (CKD-MBD) with intact parathyroid hormone (iPTH), serum calcium, 25(OH) vitamin D, and 1,25 (OH)2 vitamin D prior to decisions regarding Denosumab-bmwo treatment. Consider also assessing bone turnover status (serum markers of bone turnover or bone biopsy) to evaluate the underlying bone disease that may be present .
Denosumab-bmwo should be administered by a healthcare provider.
The recommended dose of Denosumab-bmwo is 60 mg administered as a single subcutaneous injection once every 6 months. Administer Denosumab-bmwo via subcutaneous injection in the upper arm, the upper thigh, or the abdomen. All patients should receive calcium 1000 mg daily and at least 400 IU vitamin D daily .
If a dose of Denosumab-bmwo is missed, administer the injection as soon as the patient is available. Thereafter, schedule injections every 6 months from the date of the last injection.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Denosumab-bmwo is a clear, colorless to pale yellow solution. Do not use if the solution is discolored or cloudy or if the solution contains particles or foreign particulate matter.
Prior to administration, Denosumab-bmwo may be removed from the refrigerator and brought to room temperature up to 25°C (77°F) by standing in the original carton. This generally takes 15 to 30 minutes. Do not warm Denosumab-bmwo in any other way .
Instructions for Administration of Prefilled Syringe with Safety Guard
IMPORTANT: To reduce the risk of accidental needle stick injury, each prefilled syringe has a safety guard that is automatically activated to cover the needle after you have given the injection.
Do not pull back on the plunger rod at any time.
Step 1: Remove the Needle Cap
Dispose of the needle cap right away in the nearest sharps disposal container.
DO NOT re-cap the prefilled syringe.
Step 2: Administer Subcutaneous Injection
Choose an appropriate injection site. The recommended injection sites for Denosumab-bmwo include: the outer area of the upper arms OR the upper legs (thighs) OR around the stomach area (abdomen).
Inject all of the liquid by using your thumb to push the plunger rod all the way down. …
How to take Denosumab — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Hypocalcemia
Advise the patient to adequately supplement with calcium and vitamin D and instruct them on the importance of maintaining serum calcium levels while receiving Denosumab-bmwo . Advise patients to seek prompt medical attention if they develop signs or symptoms of hypocalcemia.
Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease
Advise patients with advanced chronic kidney disease, including those who are dialysis-dependent, about the symptoms of hypocalcemia and the importance of maintaining serum calcium levels with adequate calcium and activated vitamin D supplementation. Advise these patients to have their serum calcium measured weekly for the first month after Denosumab-bmwo administration and monthly thereafter [see Dosage and Administration (2.2), Warnings and Precautions (5.1), Use in Specific Populations (8.6)].
Drug Products with Same Active Ingredient
Advise patients that if they receive Denosumab-bmwo, they should not receive other denosumab products concomitantly . …
Warnings & precautions
Do not take this medicine if: Denosumab-bmwo is contraindicated in:
Patients with hypocalcemia: Pre-existing hypocalcemia must be corrected prior to initiating therapy with Denosumab-bmwo .
Pregnant women: Denosumab products may cause fetal harm when administered to a pregnant woman. In women of reproductive potential, pregnancy testing should be performed prior to initiating treatment with Denosumab-bmwo .
Patients with hypersensitivity to denosumab products: Denosumab-bmwo is contraindicated in patients with a history of systemic hypersensitivity to any component of the product. Reactions have included anaphylaxis, facial swelling, and urticaria .
Denosumab products can cause severe hypocalcemia and fatal cases have been reported. Pre-existing hypocalcemia must be corrected prior to initiating therapy with Denosumab-bmwo. Adequately supplement all patients with calcium and vitamin D .
In patients without advanced chronic kidney disease who are predisposed to hypocalcemia and disturbances of mineral metabolism (e.g. history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malabsorption syndromes, excision of small intestine, treatment with other calcium-lowering drugs), assess serum calcium and mineral levels (phosphorus and magnesium) 10 to 14 days after Denosumab-bmwo injection. In some postmarketing cases, hypocalcemia persisted for weeks or months and required frequent monitoring and intravenous and/or oral calcium replacement, with or without vitamin D.
Patients with Advanced Chronic Kidney Disease
Patients with advanced chronic kidney disease [i.e., eGFR <30 mL/min/1.73 m2] including dialysis-dependent patients are at greater risk for severe hypocalcemia following denosumab products administration. Severe hypocalcemia resulting in hospitalization, life-threatening events and fatal cases have been reported. …
Denosumab side effects
The following serious adverse reactions are discussed below and also elsewhere in the labeling:
Severe Hypocalcemia and Mineral Metabolism Changes
Hypersensitivity
Osteonecrosis of the Jaw
Atypical Subtrochanteric and Diaphyseal Femoral Fractures
Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation
Serious Infections
Dermatologic Adverse Reactions
The most common adverse reactions reported with denosumab products in patients with postmenopausal osteoporosis are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis.
The most common adverse reactions reported with denosumab products in men with osteoporosis are back pain, arthralgia, and nasopharyngitis.
The most common adverse reactions reported with denosumab products in patients with glucocorticoid-induced osteoporosis are back pain, hypertension, bronchitis, and headache.
The most common (per patient incidence ≥ 10%) adverse reactions reported with denosumab products in patients with bone loss receiving androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer are arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been reported in clinical trials.
The most common adverse reactions leading to discontinuation of denosumab products in patients with postmenopausal osteoporosis are back pain and constipation. …
About this medicine
Denosumab-bmwo is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand). Denosumab-bmwo has an approximate molecular weight of 147 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.
Denosumab-bmwo injection is a sterile, preservative-free, clear, colorless to pale yellow solution for subcutaneous use.
Each single-dose prefilled syringe contains 60 mg denosumab-bmwo, 0.26 mg acetic acid, 0.1 mg polysorbate 20, 1.05 mg sodium acetate, 47 mg sorbitol, and Water for Injection. The pH is 5.2.
How it works: Denosumab products bind to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Denosumab products prevent RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 7a449553-105c-46a1-bb72-849d8f5b81bd. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone